| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
3,250,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Vallon Pharmaceuticals is a clinical-stage biopharmaceutical company primarily focused on the development and commercialization of biopharmaceutical products. Co. is developing medications for central nervous system disorders with a focus on abuse-deterrent medications. Co.'s primary investigational product candidate, ADAIR, is a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine (the main active ingredient in Adderall®) for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. ADAIR is designed to deter attempts to crush and snort and to provide barriers to injection while still providing the therapeutic benefit when taken orally.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Chaturvedi Vipin |
Chief Scientific Officer |
• – – |
2023-04-21 |
4 |
A |
$0.00 |
$0 |
D/D |
172,189 |
172,189 |
|
- |
|
| Hertz Walter Marc |
Chief Executive Officer |
• • • |
2023-04-21 |
4 |
A |
$0.00 |
$0 |
D/D |
385,510 |
385,510 |
|
- |
|
| Agro Albert |
Chief Medical Officer |
• – – |
2023-04-21 |
4 |
A |
$0.00 |
$0 |
D/D |
172,189 |
172,189 |
|
- |
|
| Thorell Marella |
Director |
– • – |
2022-12-13 |
4 |
D |
$0.00 |
$0 |
D/D |
(28,517) |
9,506 |
|
- |
|
| Thorell Marella |
Director |
– • – |
2022-07-01 |
4 |
A |
$0.00 |
$0 |
D/D |
38,023 |
38,023 |
|
- |
|
| Kelly Leanne M. |
Chief Financial Officer |
• – – |
2021-06-04 |
4 |
B |
$4.08 |
$6,153 |
D/D |
1,508 |
6,250 |
2.74 |
- |
|
| Kelly Leanne M. |
Chief Financial Officer |
• – – |
2021-06-03 |
4 |
B |
$4.05 |
$4,394 |
D/D |
1,085 |
4,742 |
2.66 |
- |
|
| Kelly Leanne M. |
Chief Financial Officer |
• – – |
2021-06-02 |
4 |
B |
$4.00 |
$14,628 |
D/D |
3,657 |
3,657 |
2.74 |
- |
|
| Payne Joseph E |
Director |
– • – |
2021-05-26 |
4 |
B |
$4.50 |
$30,600 |
D/D |
6,800 |
17,500 |
2.39 |
- |
|
| Payne Joseph E |
Director |
– • – |
2021-05-25 |
4 |
B |
$3.85 |
$41,195 |
D/D |
10,700 |
10,700 |
2.39 |
- |
|
| Ammer Richard |
Director |
– • – |
2021-02-12 |
4 |
A |
$6.40 |
$301,203 |
I/I |
47,063 |
47,063 |
|
- |
|
| Salmon Pharma Gmbh |
10% Owner |
– – • |
2021-02-12 |
4 |
A |
$6.40 |
$301,203 |
D/D |
47,063 |
47,063 |
|
- |
|
| Baker David Charles |
Chief Executive Officer |
• • – |
2021-02-12 |
4 |
B |
$8.00 |
$8,000 |
D/D |
1,000 |
8,843 |
2.81 |
- |
|
| Baker David Charles |
Chief Executive Officer |
• • – |
2021-02-12 |
4 |
A |
$6.40 |
$50,195 |
D/D |
7,843 |
7,843 |
|
- |
|
| Payne Joseph E |
Director |
– • • |
2021-02-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
843,750 |
|
- |
|
| Arcturus Therapeutics Holdings Inc. |
10% Owner |
– – • |
2021-02-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
843,750 |
|
- |
|
| Levi Ofir |
Director |
– • – |
2021-02-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
196,875 |
|
- |
|
| Salmon Pharma Gmbh |
10% Owner |
– – • |
2021-02-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,476,734 |
|
- |
|
| Ammer Richard |
Director |
– • • |
2021-02-09 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,476,734 |
|
- |
|
19 Records found
|
1
|
Page 1 of 1 |
|
|
